Guidelines for radioiodine therapy of differentiated thyroid cancer

@article{Luster2008GuidelinesFR,
  title={Guidelines for radioiodine therapy of differentiated thyroid cancer},
  author={Markus Luster and Susan E. M. Clarke and Markus Dietlein and Michael Lassmann and Peter Lind and Wim J. G. Oyen and Jan Tennvall and Emilio Bombardieri},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2008},
  volume={35},
  pages={1941-1959}
}
IntroductionThe purpose of the present guidelines on the radioiodine therapy (RAIT) of differentiated thyroid cancer (DTC) formulated by the European Association of Nuclear Medicine (EANM) Therapy Committee is to provide advice to nuclear medicine clinicians and other members of the DTC-treating community on how to ablate thyroid remnant or treat inoperable advanced DTC or both employing large 131-iodine (131I) activities.DiscussionFor this purpose, recommendations have been formulated based on… Expand

Paper Mentions

Interventional Clinical Trial
Thyroid nodules are a common clinical problem. Epidemiologic studies have shown the prevalence of palpable thyroid nodules to be approximately 5% in women and 1% in men living in… Expand
ConditionsDifferentiated Thyroid Carcinoma
InterventionRadiation
Radioiodine treatment of differentiated thyroid cancer related to guidelines and scientific literature
TLDR
Pending the results of the prospective trials that are currently underway, the use of 131I seems to be justified not only in high-risk patients, but also in intermediate-risk and low- risk patients. Expand
Preparing Patients for Radioiodine Treatment: Increasing Thyroid Cell Uptake and Accelerating the Excretion of Unbound Radioiodine
The therapeutic application of radioiodine 131I in postoperative ablation of the remaining thyroid tissue, as well as in the treatment of recidivism and/or local and remote metastases ofExpand
Variations in radioiodine ablation: decision-making after total thyroidectomy
TLDR
It is demonstrated that for low-risk DTC patients after thyroidectomy, some institutions offered only follow-up, while RIT with significant activities is recommended in others, and for intermediate- and high-risk patients, radioiodine treatment is generally recommended. Expand
Radioiodine Therapy in Differentiated Thyroid Cancer
TLDR
The standard approach for preparation of I-131 therapy in patients with metastases is endogenous hypothyroidism after thyroid hormone withdrawal, andications, contraindications and practical aspects of radioiodine treatment will be discussed in this review. Expand
Dosimetry and thyroid cancer: the individual dosage of radioiodine.
TLDR
Treatment of children and adolescents with radioiodine requires special precautions; individualized approaches in this setting are reviewed and new concepts for further elaborating the potential of thyroid cancer treatment using (131)I are introduced. Expand
Radioiodine Therapy.
TLDR
If applied correctly, 131I therapy in the hands of expert nuclear medicine physicians is a highly effective oncologic therapy, which has proven to represent an effective and well-tolerated procedure in the management of pediatric patients with DTC. Expand
Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option
TLDR
A safe application of this Bde-escalation^ approach is still hampered by several significant simplifications and approximations, contradictions and most importantly the lack of solid evidence to support the choices made based on stratification systems predicated on limited surgical pathology information. Expand
Radioiodine Therapy in Differentiated Thyroid Carcinoma
TLDR
The decision as to ablate or not toAblate remnant tissue (and hence to forgo an adjuvant role) in patients with minimal disease and few risk factors is undergoing revision, and the role and utilization of RAI have become increasingly complex. Expand
Radioiodine Therapy of Malignant Thyroid Diseases
TLDR
Radioiodine-131 (I-131) is used in the treatment of thyroid diseases: hyperthyroidism and differentiated thyroid cancer (DTC): papillary, follicular, Hurthle cell cancer and in patients with differentiated thyroid cancers following total thyroidectomy. Expand
Chapter 2 Radioiodine Therapy of Malignant Thyroid Diseases
Radioiodine-131 (I-131) is used in the treatment of thyroid diseases: hyperthyroidism and differentiated thyroid cancer (DTC: papillary, follicular, Hurthle cell cancer). Treatment success depends onExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 143 REFERENCES
Guidelines on radioiodine therapy for differentiated thyroid carcinoma: impact on clinical practice.
TLDR
The 1999 guideline revision appears to have had little impact on clinical practice, and further follow-up will reveal if guideline compliance had an effect on outcomes. Expand
[Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3)].
The procedure guideline for radioiodine therapy (RIT) of differentiated thyroid cancer (version 3) is the counterpart to the procedure guideline for (131)I whole-body scintigraphy (version 3) andExpand
[Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2)].
TLDR
An interdisciplinary consensus is necessary whether the new TNM-classification (UICC, 6(th) edition, 2002) will lead to modified recommendations for surgical or nuclear medicine therapy, especially for the surgical completeness and for the ablative RIT of pT1 papillary cancer. Expand
[Procedure guideline for radioiodine therapy and 131iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer].
The procedure guideline for radioiodine ((131)I) therapy and (131)I whole-body scintigraphy of differentiated thyroid cancer in paediatric patients is the counterpart to the procedure guidelinesExpand
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
TLDR
Administration of rhTSH, like thyroid hormone withdrawal, was found to stimulate expansion of the tumour, with ensuing compression of key anatomical structures and neurological, respiratory or other clinical complications, and warrants additional investigation in younger patients at earlier stages of thyroid cancer. Expand
External Beam Radiotherapy
TLDR
A systematic review of the available evidence on adjuvant RTx for DTC is presented, which does not discussRTx for medullary carcinoma, which has been reviewed elsewhere. Expand
"High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
TLDR
Use repetitive high-activity RIT with amaximum of 44.4 GBq applied during 1 yr and a maximum of 99.9 GBq accumulated activity resulted in a significant increase of hematotoxicity, however, during the follow-up period, no clinical symptoms possibly related to low blood counts were seen in patients with advanced differentiated thyroid carcinoma. Expand
Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma.
TLDR
Bexarotene partially restores I-131 uptake in metastases of DTC, and the clinical relevance of this observation may be limited due to the differential responses of the different metastases within each patient and the low intensity of I- 131 uptake. Expand
Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone
TLDR
It is concluded that rhTSH-stimulated high-dose radioiodine for remnant ablation or tumor treatment is safe, feasible and seemingly effective, enhancing quality of life and offering reasonable palliation in patients with advanced disease. Expand
Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study
TLDR
The encouraging results of the study and the low rate of side-effects with good tolerability of retinoids warrant further studies with altered inclusion criteria and employment of other redifferentiating drugs or combinations of agents. Expand
...
1
2
3
4
5
...